The combination of Teliso-V and erlotinib in patients with c-MET-positive, EGFR-mutant NSCLC who had progressed on prior EGFR-TKI showed antitumor activity, with an ORR of 32.1% in the EGFR-mutant population and 52.6% in high-c-Met tumors, a manageable toxicity profile, and neuropathies being the most common treatment-related adverse event (AE) [96]. Here, MET is linked to non-small cell lung carcinoma.